Latest News

Noxopharm announced that its lead experimental therapy, SOF-SKN, will advance to an extension clinical study in patients with cutaneous lupus erythematosus, a painful, disfiguring skin condition for which no targeted treatment currently exists.

Six patients who had lived with binge eating disorder for as long as two decades sat down for two infusions of an experimental psychedelic drug. Three months later, all of them were still doing better. Half of them had not binged once.

Perth-based medical technology company Proteomics International has begun selling two of its diagnostic blood tests directly to patients in Western Australia and the Northern Territory, marking the first real-world rollout of its Promarker portfolio under a new national distribution partnership with pathology giant Healius.

Telix Pharmaceuticals has secured landmark approval from the United States Food and Drug Administration for Pixclara, making it the first FDA-sanctioned imaging agent for glioma, the most common form of brain cancer.

AusBiotech has welcomed concessions to changes to the R&D Tax Incentive and Capital Gains Tax but remains concerned about the potential impact on emerging life sciences companies.

According to the document released in response to a Freedom of Information request, the firm held 24 active contracts with the department, worth a combined $37.3 million as at 22 May 2026.

As health spokesperson, Stephenson has been a visible advocate for ACT's 'Closing the Medicines Gap' policy, released in July, that commits the party to a significant increase in Pharmac funding.

This week, we mark a significant anniversary, discuss the risks of missing the opportunity that artificial intelligence offers to speed access to healthcare, and explore why some might be reluctant to embrace it. The wonderful irony of the phrase of the week.

Australians living with a rare genetic form of motor neurone disease will gain access to an innovative treatment from 1 October, with the reimbursement of Biogen's QALSODY (tofersen).

In a further expansion of pharmacists' role, the government announced a new care trial that will let participating pharmacists treat ear infections, provide wound care, and help manage chronic conditions including hypertension and chronic obstructive pulmonary disease.

AI in healthcare is being decided right now. Are you leading or following? On 9 November in Sydney leaders in pharma, biotech and health policy in Australia will be in one room, working through...

The United States is marking an important legislative milestone that unlocked university-led innovation, while some in Australia still maintain that the government deserves pricing consideration for commercialised products that may have received some funding support in the distant past.